How to buy Avadel Pharmaceuticals stock | $6.82

Avadel Pharmaceuticals plc is a drug manufacturers-specialty & generic business based in the US. Avadel Pharmaceuticals shares (AVDL) are listed on the NASDAQ and all prices are listed in US Dollars. Avadel Pharmaceuticals employs 50 staff and has a trailing 12-month revenue of around USD$33.3 million.

How to buy shares in Avadel Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Avadel Pharmaceuticals. Find the stock by name or ticker symbol: AVDL. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Avadel Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$6.82, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Avadel Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Avadel Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Avadel Pharmaceuticals share price

Use our graph to track the performance of AVDL stocks over time.

Avadel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-26.

Latest market close	USD$6.82
52-week range	USD$4 - USD$12
50-day moving average	USD$6.8932
200-day moving average	USD$6.9692
Wall St. target price	USD$17.88
PE ratio	21.2963
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$0.324

Buy Avadel Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Avadel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Avadel Pharmaceuticals plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Avadel Pharmaceuticals price performance over time

Historical closes compared with the close of $6.82 from 2021-01-11

1 week (2021-01-07)	-0.58%
1 month (2020-12-16)	-6.32%
3 months (2020-10-16)	24.91%
6 months (2020-07-16)	-15.80%

1 year (2020-01-16)	-11.08%
2 years (2019-01-16)	165.37%
3 years (2018-01-16)	10.61
5 years (2016-01-15)	10.04

Is Avadel Pharmaceuticals under- or over-valued?

Valuing Avadel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avadel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Avadel Pharmaceuticals's P/E ratio

Avadel Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Avadel Pharmaceuticals shares trade at around 21x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Avadel Pharmaceuticals's PEG ratio

Avadel Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Avadel Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Avadel Pharmaceuticals financials

Revenue TTM	USD$33.3 million
Gross profit TTM	USD$47.1 million
Return on assets TTM	-7.61%
Return on equity TTM	21.59%
Profit margin	46.71%
Book value	$2.939
Market capitalisation	USD$402.1 million

TTM: trailing 12 months

Shorting Avadel Pharmaceuticals shares

There are currently 4.1 million Avadel Pharmaceuticals shares held short by investors – that's known as Avadel Pharmaceuticals's "short interest". This figure is 6.5% down from 4.4 million last month.

There are a few different ways that this level of interest in shorting Avadel Pharmaceuticals shares can be evaluated.

Avadel Pharmaceuticals's "short interest ratio" (SIR)

Avadel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Avadel Pharmaceuticals shares currently shorted divided by the average quantity of Avadel Pharmaceuticals shares traded daily (recently around 483229.52941176). Avadel Pharmaceuticals's SIR currently stands at 8.5. In other words for every 100,000 Avadel Pharmaceuticals shares traded daily on the market, roughly 8500 shares are currently held short.

However Avadel Pharmaceuticals's short interest can also be evaluated against the total number of Avadel Pharmaceuticals shares, or, against the total number of tradable Avadel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avadel Pharmaceuticals's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Avadel Pharmaceuticals shares in existence, roughly 70 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Avadel Pharmaceuticals shares, roughly 0 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Avadel Pharmaceuticals.

Find out more about how you can short Avadel Pharmaceuticals stock.

Avadel Pharmaceuticals share dividends

We're not expecting Avadel Pharmaceuticals to pay a dividend over the next 12 months.

Avadel Pharmaceuticals share price volatility

Over the last 12 months, Avadel Pharmaceuticals's shares have ranged in value from as little as $4 up to $12. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avadel Pharmaceuticals's is 1.6063. This would suggest that Avadel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Avadel Pharmaceuticals overview

Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Frequently asked questions

• What percentage of Avadel Pharmaceuticals is owned by insiders or institutions?

  Currently 5.891% of Avadel Pharmaceuticals shares are held by insiders and 55.962% by institutions.

• How many people work for Avadel Pharmaceuticals?

  Latest data suggests 50 work at Avadel Pharmaceuticals.

• When does the fiscal year end for Avadel Pharmaceuticals?

  Avadel Pharmaceuticals's fiscal year ends in December.

• Where is Avadel Pharmaceuticals based?

  Avadel Pharmaceuticals's address is: 10 Earlsfort Terrace, Dublin, Ireland, 2

• What is Avadel Pharmaceuticals's ISIN number?

  Avadel Pharmaceuticals's international securities identification number is: US05337M1045

• What is Avadel Pharmaceuticals's CUSIP number?

  Avadel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 05337M104